

Trust Headquarters
Russell's Hall Hospital
Dudley
West Midlands
DY1 2HQ

Ref: FOI-042026-0002385

Date: 27.05.2026

Address / Email:

Dear

Request Under Freedom of Information Act 2000

Thank you for requesting information under the Freedom of Information Act 2000.

I am conducting analysis on treatment with immunology medicines and kindly request your help.

I would be grateful if you could tell me how many patients were treated between January and March 2026 for the list of drugs named in the questions below.

Please fill in the template below with the number of patients or a format of your choice. Please include data for all hospitals in your organisation.

IMMUNOLOGY

Q1. In the 3-months, Jan26-Mar26, the following number patients were issued the listed treatments (for any condition):

Treatment	PT Count
Adalimumab	860
Etrasimod	0
Filgotinib	26
Golimumab	21
Guselkumab	21
Infliximab (Biosimilars)	128
Infliximab (Remicade)	0
Mirikizumab	2
Ozanimod	0
Risankizumab	66
Tofacitinib	5
Upadacitinib	180
Ustekinumab	280
Vedolizumab	133

Q2. In the 3-months, Jan26-Mar26, the following number patients were issued the listed treatments (for any condition) by the Gastroenterology Department:

Treatment	PT Count
Adalimumab	220
Etrasimod	0
Filgotinib	0
Golimumab	0
Guselkumab	0
Infliximab (Biosimilars)	108
Infliximab (Remicade)	0
Mirikizumab	2
Ozanimod	0
Risankizumab	44
Tofacitinib	2
Upadacitinib	116
Ustekinumab	243
Vedolizumab	133

Q3. How many patients with Crohn’s Disease or Ulcerative Colitis, in total regardless of department / clinic, were treated with the following drugs between 1st Jan 2026 and 31st March 2026, or the latest 3-month period for which you have data?

The data held by Pharmacy is not linked to indication therefore we cannot answer any question about treatments of specific conditions.

BIOLOGICS

Q1. In the 3-months, Jan26-Mar26, the following number patients were issued the listed treatments (for any condition):

Treatment	PT Count
1.1 Benralizumab (Fasenra)	76
1.2 Depemokimab (Exdensur)	0
1.3 Dupilumab (Dupixent)	83
1.4 Lebrikizumab (Ebglyss)	38
1.5 Mepolizumab (Nucala)	89
1.6 Omalizumab (Xolair)	65
1.7 Reslizumab (Cinqaero)	0
1.8 Tezepelumab (Tezspire)	82

Q2. How many patients were treated for severe asthma, COPD, CRwNP with the following medicines in the 3 months between the start of Jan 2026 and end of Mar 2026?

The data held by Pharmacy is not linked to indication therefore we cannot answer any question about treatments of specific conditions.

Q3. How many patients were treated for Atopic Dermatitis with the following medicines in the 3 months between the start of Jan 2026 and end of Mar 2026?

The data held by Pharmacy is not linked to indication therefore we cannot answer any question about treatments of specific conditions.

Q4. In the 3-months, Jan26-Mar26, the following number patients were issued the listed treatments (for any condition) by the named departments:

□

Treatment	PT Count (Respiratory Dept)	PT Count (Dermatology Dept)	PT Count (Other Depts)
4.1 Benralizumab (Fasenra)	76	0	0
4.2 Depemokimab (Exdensur)	0	0	0
4.3 Dupilumab (Dupixent)	8	75	0
4.4 Lebrikizumab (Ebglyss)	0	38	0
4.5 Mepolizumab (Nucala)	89	0	0
4.6 Omalizumab (Xolair)	20	0	45
4.7 Reslizumab (Cinqaero)	0	0	0
4.8 Tezepelumab (Tezspire)	82	0	0

If you are dissatisfied with our response, you have the right to appeal in line with guidance from the Information Commissioner. In the first instance you may contact the Information Governance Manager of the Trust.

Information Governance Manager
Trust Headquarters
Russell’s Hall Hospital
Dudley
West Midlands
DY1 2HQ
Email: dgft.dpo@nhs.net

Should you disagree with the contents of our response to your appeal, you have the right to appeal to the Information Commissioners Office at.

Information Commissioners Office
Wycliffe House
Water Lane
Wilmslow
Cheshire
SK9 5AF
Tel: 0303 123 1113
www.ico.org.uk

If you require further clarification, please do not hesitate to contact us.

Yours sincerely

Freedom of Information Team
The Dudley Group NHS Foundation Trust